MXCT - MaxCyte Inc. (MXCT) Q4 2023 Earnings Call Transcript
2024-03-12 22:40:19 ET
MaxCyte, Inc. (MXCT)
Q4 2023 Earnings Conference Call
March 12, 2024 16:30 ET
Company Participants
Sean Menarguez - Head of Investor Relations
Maher Masoud - President & Chief Executive Officer
Douglas Swirsky - Chief Financial Officer
Conference Call Participants
Jacob Johnson - Stephens
Dan Arias - Stiefel
Matt Larew - William Blair
Mark Massaro - BTIG
Steven Mah - TD Cowen
Matt Hewitt - Craig-Hallum
Presentation
Operator
Good day and thank you for standing by. Welcome to the MaxCyte Fourth Quarter Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Sean Menarguez, Senior Director of Innovation and Business Development. Please go ahead.
Sean Menarguez
Well, thank you and good afternoon, everyone. My name is Sean Menarguez and I'm the Senior Director of Innovation and Business Development here at MaxCyte. Thank you all for participating in today's conference call. On the call from MaxCyte, we have Maher Masoud, President and Chief Executive Officer; and Douglas J. Swirsky, Chief Financial Officer. Earlier today, MaxCyte released financial results for the fourth quarter and full year ended December 31, 2023. A copy of the press release is available on the company's website.
Before we begin, I need to read the following statement. Statements or comments made during this call may be forward-looking statements within the meaning of federal securities laws. Any statements other than statements of historical facts provided on this call, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations are forward-looking statements. These statements about us or our industry involve substantial known and unknown risks, uncertainties and assumptions, including those that are discussed in detail in our annual report on Form 10-K and elsewhere in our SEC filings that may cause our actual results, performance or achievements to be materially different than any other future results, performance or achievements expressed or implied by such statements. These statements are inherently uncertain and investors are cautioned not to unduly rely on these statements. The company undertakes no obligation to publicly update any forward-looking statements, whether because of new information, future events or otherwise except as required by law....
MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript